New records are added at each update and some records have been modified and updated.Įntries may include select bibliography only. Please note that only selected manuscripts in the Additional collection and no manuscripts in the Cotton collection are included in the Catalogue. Please see guidance notes on Access and Reuse. download digital images for further reuse such as in educational contexts, placing on your blog or sharing with others. check the illustrated glossaries of terms. explore the virtual exhibitions of various aspects of the British Library's western illuminated manuscript holdings and perform an advanced search using different types or combinations of information look for information about a particular manuscript if you know its collection name and manuscript number perform a simple search using keywords and dates identifier: NCT02264574. perform a quick search (this searches for a word or number in all sections of each catalogue entry, including images) In this final analysis with up to 52 months of follow-up (median 45 months), ibrutinib plus obinutuzumab showed sustained clinical benefit, in terms of progression- free survival, in first-line treatment of chronic lymphocytic leukemia, including in patients with high-risk features. As is typical for ibrutinib-based regimens, common grade ≥3 adverse events were most prevalent in the first 6 months of ibrutinib plus obinutuzumab treatment and generally decreased over time, except for hypertension. With a median treatment duration of 42 months, 13 months longer than the primary analysis, no new safety signals were identified for ibrutinib. The best overall rate of undetectable minimal residual disease (<0.01% by flow cytometry) remained higher with ibrutinib plus obinutuzumab (38%) than with chlorambucil plus obinutuzumab (25%). After a median follow-up of 45 months (range, 0.2-52), median progression-free survival continued to be significantly longer in the ibrutinib plus obinutuzumab arm than in the chlorambucil plus obinutuzumab arm (median not reached versus 22 months hazard ratio=0.25 95% confidence interval: 0.16-0.39 P<0.0001). Patients received oral ibrutinib 420 mg once daily until disease progression or unacceptable toxicity or six cycles of oral chlorambucil, each in combination with six cycles of intravenous obinutuzumab. Eligible patients were aged ≥65 years, or <65 years with coexisting conditions. ILLUMINATE is a randomized, open-label phase III study of ibrutinib plus obinutuzumab (n=113) versus chlorambucil plus obinutuzumab (n=116) as first-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. 13 Sarah Cannon Research Institute, Nashville, TN, USA.12 Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.11 Barts Cancer Institute, London, United Kingdom.10 Princess Alexandra Hospital, Brisbane, Queensland, Australia.9 Almazov National Medical Research Centre, St.8 University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic.7 Department of Internal Medicine, Haematology, University Hospital and Medical School Hradec, Králové, Czech Republic.6 University of Alberta Hospital, Edmonton, Alberta, Canada.5 Tennessee Oncology, Chattanooga, TN, USA.4 Niguarda Ca' Granda Hospital, Milan, Italy.3 Dokuz Eylul University, Division of Hematology, Izmir, Turkey.2 3rd Medical Department, Paracelsus Medical University, Salzburg Cancer Research Institute-CCCIT, Salzburg, Austria. 1 Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |